%PDF-1.4
%
4 0 obj
<TPR-NTRK1 Fusion Treated with Larotrectinib)/Trapped/False>>
endobj
5 0 obj
<>stream
Mançano B.M.; dos Reis M.B.; Moreno D.A.; de Paula F.E.; de Almeida Junior C.R.; Cavalcante C.E.B.; Zanon M.F.; Santana I.V.V.; Matsushita M.M.; Reis R.M.
A Unique Case Report of Infant-Type Hemispheric Glioma (Gliosarcoma Subtype) with <b><i>TPR</i></b>-<b><i>NTRK1</i></b> Fusion Treated with Larotrectinib
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.<br />
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.<br />
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Herein, we present a rare case of a nine-month-old boy diagnosed with infant-type hemispheric glioma (gliosarcoma subtype) at the left frontal lobe. Following subtotal resection, the patient started chemotherapy with the BABY POG protocol. We describe the clinical diagnosis, histological characteristics, radiological features, molecular aspects, and management of this tumor. A comprehensive molecular analysis on the tumor tissue showed a TPR-NTRK1 gene fusion. The patient was treated with a TRK inhibitor, larotrectinib, and exhibited a stable disease with residual lesion following 8 months of target therapy. The present study is the first report of an infantile gliosarcoma harboring NTRK1 rearrangement treated with larotrectinib.
Infantile gliosarcoma
NTRK fusion
Targeted therapy
endstream
endobj
6 0 obj
<>stream
x+ |
endstream
endobj
7 0 obj
<>stream
x}
0EE<v),Z#`o"EĹÅ9à&t0Y82`9G+G*?,P4@fJ|nM/I.BNm0:TO:BMj^Hʥxu*T?dkC?
endstream
endobj
8 0 obj
<>stream
x+ |
endstream
endobj
9 0 obj
<>stream
x}
0EE<v),Z#`o"EĹÅ9à&t0Y$2`9G+G*?,P4@fJ|nM/I.BNm0:TO:BMj^Hʥxu*T?dkC]?
endstream
endobj
10 0 obj
<>stream
x+ |
endstream
endobj
11 0 obj
<>stream
x}
0EE<v),Z#`o"EĹÅ9à&t2t#a:4)dT s5W$R5T$YhZ7"̔Vܜ?_\Ѕ>stream
x+ |
endstream
endobj
13 0 obj
<>stream
x}M@E+82j)LжlR(̈́A;CE>ަF2tdeH99kn$QJk@kд
5EdʖՄdrzh6^ơanjR\R.5cc,,Ƕ#R?
endstream
endobj
14 0 obj
<>stream
x+ |
endstream
endobj
15 0 obj
<>stream
x}
0EE<v),Z#`o"EĹÅ9à&trt#a:4Ȩ9k$IJkHf+/~o[óDCѴnD)94$9ylPzT?y
5y!)j>)ש`B@BcS
C^}?
endstream
endobj
16 0 obj
<>stream
x+ |
endstream
endobj
17 0 obj
<>stream
x}
@;nB]6JIsE oc@xp$PLlmǐq
{f4m/O1>YlWskeUNQp@Exi_?X<=wB"sͥ\ͫc.DqR'1|F!P
)RRMed[H*?
endstream
endobj
18 0 obj
<>stream
x+ |
endstream
endobj
19 0 obj
<>stream
x}M@+c\mcQH٠kfP pa`ށAI@3@ߐC*3#c͝%
*$Mjow݀2QZKsjٷY^ۡp\ͫS*Ԥ晤\j \ǂ +]G5| L?
endstream
endobj
20 0 obj
<>stream
x+ |
endstream
endobj
21 0 obj
<>stream
x}M@+c\mcQH٠kFP pa`ށAI`yv %k3
U0gGB; KR5THnX75NEdJՄ#I]ɳ[{jvWTI3I4T322WlkH P?
endstream
endobj
24 0 obj
<>stream
HW]sۺ}Kg)Q$N&iN't Аvt}EoǓ_ϳgw\z۔Ք?+쭺/f铘>yCO۫U4Uyjh\ܰuy5Jz9K%qD^4NglIsƆ)K(YL(MWNjי"m$bVMOX-i#}!:S%7k8ĵe$ᚩ-jV3}|R}Xo?C;}τ"#X.x^I7Ivt|h.+fRi1B?13ғ.{
,UE'=֢~:_gҹv*fUY˒iեo?]OAʌᒍ(OSrOۧ9- ^4w_పeWXQOLf[exeh.rawןCdEB&%~Zf3%y7Ip\fֹ`